Jim Fish
Analyst · Raymond James. Your line is open
Yes. So the 5% to 7% is a number that we gave in 2019 with Investor Day, and we've actually been -- over the last couple of years, been outperforming that organically. But if you -- the reason we're as excited as we are about 2025, 2026, 2027 is that when you look at a couple of things. First of all, you look at -- you just talked through with Tara, the sustainability investments. As she said, CapEx, you had the numbers just about exactly right. We probably have about $700 million left in CapEx, maybe a little bit more than that. And most of that happens next year. So you can expect to see a pretty substantial uptick in free cash -- in the free cash flow component. And when I say most of that occurs next year, that is still lower in terms of CapEx than this year because this year is going to be call it, $900 million for those sustainability investments. Next year will be something lower than that. And then 2026 will be significantly lower than that in terms of CapEx. And at the same time, you see the EBITDA really, really kicking up. We do have most of these plants, it seems rolling on in the fourth quarter. So we're not getting the impact of EBITDA in that year. This year is no exception to that with four of the five coming online in the fourth quarter. Kind of the same thing for next year. A number of plants are coming online in the fourth quarter. But we do fully expect to see $800 million by the time we -- the first full year of that will be 2027. You add to that Stericycle, we've had 4.5 months to look at it. We're even more enthusiastic about the strategic side of Stericycle than we were when we announced this 4.5 months ago. Rafael and his team have had a lot of opportunity to look into this. In addition to looking at their core business, which we said four months ago was really just kind of a fourth line of business for us, and we now believe that even more after spending 4.5 months on it. The synergies piece, which we said initially, we thought might be $125 million over three years. We now are pretty convinced that, that's a conservative number. I don't know exactly what that number is going to be yet, and we'll give you more insight into that with guidance in 2025. But look, I mean, the best example is SG&A. We baked in about $40 million worth of SG&A synergies there in the original $125 million. And that takes their SG&A number from 22% of revenue down to 19%. We're reporting 8.9% ourselves today, so you can understand our optimism around synergies. And then John talked a lot about the use of technology. It's something that we probably five years ago, started recognizing that there was -- particularly with these trade type positions, there was kind of an impending shortage coming. And so we started investing in technology to -- when those positions would attrit away from us that we wouldn't have to replace them, that we would use technology. And hence, the investments that we've made over the last five years in technology. And those have really all started to show up. You've heard John talk a lot about, I think, you said four consecutive quarters of sub-61% OpEx as a percent of revenue. That is largely driven by our pricing programs, but also by our cost improvement on the efficiency side. You combine all of those plus still a pretty robust market out there for tuck-in acquisitions. And you can see why we're really, really optimistic. No matter what happens with the election, no matter what happens with the economy, barring a disastrous geopolitical events, we're very optimistic about 2025, 2026, 2027.